Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study

Peer Review reports

Original Submission
8 Nov 2022	Submitted	Original manuscript
7 Mar 2023	Reviewed	Reviewer Report - M Hesse
17 Apr 2023	Reviewed	Reviewer Report - Marc Auriacombe
5 Jun 2023	Author responded	Author comments - Bernadette Hard
Resubmission - Version 2
5 Jun 2023	Submitted	Manuscript version 2
Publishing
20 Jun 2023	Editorially accepted
4 Jul 2023	Article published	10.1186/s40814-023-01348-5

Back to article page